Managing obesity with nutrition, pharmacotherapy and bariatric surgery

April 28, 2022

1 min watch


Source: Healio Interviews

Disclosures: Stanford reports serving as a medical adviser for Boehringer Ingelheim, Calibrate, Coral Health, Eli Lilly & Co., Gelesis, GoodRX, Novo Nordisk and Pfizer.

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In this video, Healio Primary Care Peer Perspective Board Member Fatima Cody Stanford, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS, discusses her presentations on obesity from the ACP Internal Medicine Meeting.

Stanford is an obesity medicine physician and director of equity for the endocrine division at Massachusetts General Hospital.

In one presentation, she will discuss the appropriate use of GLP1-agonists in patients with obesity, including those who underwent bariatric surgery. Most anti-obesity pharmacotherapies can be classified into three primary groups, according to Stanford: centrally acting medications that impair dietary intake; medications that act peripherally to impair food absorption; and medications that increase energy expenditure. As 25% to 35% of bariatric surgery patients have significant weight gain within 2 to 5 years after their surgery, pharmacotherapy may be an effective adjunct.

In the second presentation, Stanford and colleagues will discuss the impact of eating habits on global health. The proportion of adults with overweight or obesity has continued to rise during the last 2 decades.

“This will be a broad presentation really looking at all the issues we are seeing country to country as it relates to issues like overweight and obesity but also malnutrition and food insecurity,” Stanford said.


Brook R, et al. MSFM: Neurology, psychiatry, and metabolism. Presented at: ACP Internal Medicine Meeting; April 28-30, 2022; Chicago.

Duffy W, et al. Food as a medical intervention. Presented at: ACP Internal Medicine Meeting; April 28-30, 2022; Chicago.

Leave a Comment